Results 81 to 90 of about 43,704 (225)

microRNAs and Acute Myeloid Leukemia Chemoresistance: A Mechanistic Overview

Frontiers in Oncology, 2017
Up until the early 2000s, a functional role for microRNAs (miRNAs) was yet to be elucidated. With the advent of increasingly high-throughput and precise RNA-sequencing techniques within the last two decades, it has become well established that miRNAs can
Martino Marco Gabra, Leonardo Salmena, Leonardo Salmena   +2 more
doaj   +1 more source

Before Guillain‐Barre Syndrome Is Attributed to a CMV Infection, the Diagnosis Must Be Confirmed and Other Causes Must Be Ruled Out

The Kaohsiung Journal of Medical Sciences, EarlyView.
Josef Finsterer
wiley   +1 more source

Successful allo‐hematopoietic stem cell transplantation using washed hematopoietic stem cells in a pediatric patient complicated by acute myeloid leukemia and severe anaphylaxis to blood product

Pediatric Investigation, EarlyView.
Jieyu Tian, Guanghua Zhu, Maoquan Qin, Chenguang Jia, Shuxuan Ma, Bin Wang, Yanhui Luo   +6 more
wiley   +1 more source

Comparison of outcomes after DA‐EPOCH‐R or GMALL high‐intensity therapy for front‐line treatment of Burkitt lymphoma: A retrospective cohort

British Journal of Haematology, EarlyView.
In this retrospective cohort of adult Burkitt lymphoma, DA‐EPOCH‐R showed no signal of inferior survival or relapse risk compared with GMALL‐based high‐intensity therapy. Outcomes were driven mainly by established prognostic factors, particularly age, advanced stage and Burkitt lymphoma International Prognostic Index.
Eduard Schulz, Florian Posch, Kristina Friedrich, Peter Neumeister, Katharina T. Prochazka   +4 more
wiley   +1 more source

Prognostic impact of blood Epstein–Barr virus‐DNA in patients with peripheral T‐cell lymphoma, not otherwise specified

British Journal of Haematology, EarlyView.
Summary Peripheral T‐cell lymphoma, not otherwise specified (PTCL‐NOS), is a heterogeneous nodal T‐ and natural killer (NK)‐cell lymphoma with limited prognostic biomarkers. A subset of PTCL‐NOS characterized by Epstein–Barr virus (EBV) involvement in tumour cells has recently been recognized as EBV‐positive nodal T‐ and NK‐cell lymphoma (EBV+ nPTCL ...
Hyunseok Yoon, Hyungwoo Cho, In Hye Song, Sejin Kim, So Heun Lee, Kyoungmin Lee, Shin Kim, Chan‐Sik Park, Eun Jin Chae, Kyung Won Kim, Jin‐Sook Ryu, Sang‐Wook Lee, Jaewon Hyung, Heounjeong Go, Dok Hyun Yoon   +14 more
wiley   +1 more source

Efficacy and safety of stem cell mobilization with etoposide +cytarabine plus G-CSF in poor mobilizers with relapsed or refractory lymphoma

Frontiers in Immunology
BackgroundAutologous stem cell transplantation (ASCT) is a potentially curative strategy for relapse or refractory(r/r) aggressive lymphoma. However, a proportion of lymphoma patients who are at high risk of mobilization failure fail to mobilize stem ...
Zhijuan Zhu, Xiaofan Li, Xiaofan Li, Xiaohong Yuan, Xianling Chen, Ting Lin, Xiangli Guo, Nainong Li, Nainong Li   +8 more
doaj   +1 more source

Quizartinib Resistance Mutations and Treatment Outcomes in Relapsed or Refractory FLT3‐ITD–Positive AML

Cancer Science, EarlyView.
ABSTRACT Quizartinib is a FMS‐like tyrosine kinase 3 (FLT3) inhibitor indicated for FLT3 internal tandem duplication (FLT3‐ITD)–positive acute myeloid leukemia (AML). We aimed to evaluate quizartinib resistance mechanisms, in addition to efficacy and safety outcomes, in patients with relapsed or refractory FLT3‐ITD–positive AML.
Yuichiro Semba, Toshihiro Miyamoto, Senji Kasahara, Yoshikane Kikushige, Takahiro Maeda, Goichi Yoshimoto, Shuichi Ota, Akio Saito, Yuho Najima, Hiroki Hosoi, Daigo Niiya, Koji Kato, Koji Nagafuji, Takashi Akasaka, Tomohiko Kamimura, Atsushi Takita, Maiko Narahara, Tadashi Toki, Koichi Iwanaga, Koji Yonemoto, Mine Harada, Koichi Akashi   +21 more
wiley   +1 more source

A 3D Bioprinted Platform That Maintains the Functional Integrity of Primary AML Cells

Cell Proliferation, EarlyView.
This study presents a 3D bioprinted platform using gelatin‐hyaluronic acid hydrogels to enhance primary AML cell survival and proliferation while preserving stem‐like properties in vitro. By recapitulating in vivo‐like metabolic activity and drug resistance, this system offers a robust tool for preclinical drug screening and personalised therapy ...
Wanling Huang, Bo Deng, Nini Guo, Yiyi Ding, Zhangjingwen Xu, Yiwen Lu, Yue Ma, Qian Ren, Nan Wang, Pengyu Huang, Xiaotong Ma   +10 more
wiley   +1 more source

Post‐Transplant Bendamustine as a Platform for Immune Modulation After Allogeneic Hematopoietic Cell Transplantation

European Journal of Haematology, EarlyView.
ABSTRACT Post‐transplant cyclophosphamide (PT‐CY) remains the standard of care for graft‐versus‐host disease (GvHD) prophylaxis in haploidentical hematopoietic cell transplantation (HCT), yet relapse, delayed immune reconstitution, infections, and organ toxicity represent persistent and clinically meaningful limitations.
Megan J. Cracchiolo, Richard J. Simpson, Emmanuel Katsanis   +2 more
wiley   +1 more source

Pure erythroid leukaemia in early infancy: Diagnostic pitfalls and clinical challenges

British Journal of Haematology, EarlyView.
Riccardo De Carli, Baptiste Le Calvez, Elodie Lainey, Catherine Settegrana, Marion Strullu, Marlene Pouthier   +5 more
wiley   +1 more source